Kang Lee1, Il-Yeong Hwang2, Chang Hyun Ryu3, Jae Woo Lee4, Seung Woo Kang2. 1. 1 Department of Orthopaedic Surgery, Chamjoeunhospital, Gwangju, Gyunggi, Republic of Korea. 2. 2 Department of Orthopedic Surgery, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Republic of Korea. 3. 3 Department of Orthopaedic Surgery, SeoulChuk Hospital, Seoul, Republic of Korea. 4. 4 Department of Orthopaedic Surgery, Kangwon National University, Gangwon, Republic of Korea.
Abstract
BACKGROUND: Morton's neuroma is one of the common causes of forefoot pain. In the present study, hyaluronic acid injection was performed on patients to determine the efficacy and adverse effects of hyaluronic acid in management of Morton's neuroma. METHODS: Eighty-three patients with Morton's neuroma in their third intermetatarsal space with definite Mulder's click were included in the study. Those with severe forefoot deformities such as forefoot cavus or hallux valgus on plain X-rays were excluded. Ultrasound-guided hyaluronic acid injections were performed on all patients weekly for 3 weeks. Pain during walking using visual analogue scale (VAS) and AOFAS Forefoot Scale were prospectively evaluated preinjection, and at 2, 4, 6, 12 months postinjection. RESULTS: Significant improvement in VAS and AOFAS Forefoot Scale were seen overall at 2 months after hyaluronic acid injections ( P < .05). Then, there were almost no changes after 4 months, continuing until 12 months. The mean VAS was decreased from 73.1 initially to 23.0 at 12 months and AOFAS Forefoot Scale was increased from 32.2 to 86.5. There were no complications which occurred. CONCLUSION: In the present study, ultrasound-guided hyaluronic injection was clinically effective for pain relief and functional improvement for at least 12 months in patients with Morton's neuroma. However, numbness associated with Morton's neuroma should be addressed more cautiously since it may persist without much improvement. LEVEL OF EVIDENCE: Level IV, retrospective case series.
BACKGROUND:Morton's neuroma is one of the common causes of forefoot pain. In the present study, hyaluronic acid injection was performed on patients to determine the efficacy and adverse effects of hyaluronic acid in management of Morton's neuroma. METHODS: Eighty-three patients with Morton's neuroma in their third intermetatarsal space with definite Mulder's click were included in the study. Those with severe forefoot deformities such as forefoot cavus or hallux valgus on plain X-rays were excluded. Ultrasound-guided hyaluronic acid injections were performed on all patients weekly for 3 weeks. Pain during walking using visual analogue scale (VAS) and AOFAS Forefoot Scale were prospectively evaluated preinjection, and at 2, 4, 6, 12 months postinjection. RESULTS: Significant improvement in VAS and AOFAS Forefoot Scale were seen overall at 2 months after hyaluronic acid injections ( P < .05). Then, there were almost no changes after 4 months, continuing until 12 months. The mean VAS was decreased from 73.1 initially to 23.0 at 12 months and AOFAS Forefoot Scale was increased from 32.2 to 86.5. There were no complications which occurred. CONCLUSION: In the present study, ultrasound-guided hyaluronic injection was clinically effective for pain relief and functional improvement for at least 12 months in patients with Morton's neuroma. However, numbness associated with Morton's neuroma should be addressed more cautiously since it may persist without much improvement. LEVEL OF EVIDENCE: Level IV, retrospective case series.
Authors: María Del Mar Ruiz-Herrera; Félix Marcos-Tejedor; Alberto Aldana-Caballero; César Calvo-Lobo; David Rodriguez-Sanz; Simone Moroni; Marko Konschake; Alicia Mohedano-Moriano; Javier Aceituno-Gómez; Juan José Criado-Álvarez Journal: J Clin Med Date: 2022-05-02 Impact factor: 4.964
Authors: Ivan Urits; Daniel Smoots; Henry Franscioni; Anjana Patel; Nathan Fackler; Seth Wiley; Amnon A Berger; Hisham Kassem; Richard D Urman; Laxmaiah Manchikanti; Alaa Abd-Elsayed; Alan D Kaye; Omar Viswanath Journal: Pain Ther Date: 2020-02-27
Authors: María Del Mar Ruiz-Herrera; Juan José Criado-Álvarez; Mario Suarez-Ortiz; Marko Konschake; Simone Moroni; Félix Marcos-Tejedor Journal: Diagnostics (Basel) Date: 2022-06-01